Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiqi Tongluo capsule is a Traditional Chinese Medicine (TCM) formulation developed by the Shanghai Municipal Hospital of Traditional Chinese Medicine. It is primarily indicated for the prevention of coronary artery restenosis in patients with acute coronary syndrome (ACS) following percutaneous coronary intervention (PCI). The capsule is designed to replenish Qi and unblock collaterals, which in a clinical context translates to improving microcirculation, reducing vascular inflammation, and inhibiting the proliferation of vascular smooth muscle cells that contribute to stent restenosis. It has been evaluated in multicenter randomized controlled trials in China to assess its efficacy in reducing major adverse cardiovascular events (MACE) and the incidence of restenosis after stenting.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yiqi Tongluo capsule.